ARDANA BIOSCIENCE
DEAD

Serial Number

76178478

Owner

ARDANA BIOSCIENCE LIMITED

Attorney

Mark H. Tidman

Filing Date

Dec 11, 2000

Add to watchlist:

No watchlists yet
View on USPTO

ARDANA BIOSCIENCE Trademark

Serial Number: 76178478 • Registration: 3147061

ARDANA BIOSCIENCE is a trademark filed by ARDANA BIOSCIENCE LIMITED on December 11, 2000. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

ARDANA BIOSCIENCE LIMITED (2 trademarks)

20 PARK CRESENT
LONDON W1N 4AL , GB

Entity Type: 03

Coarsedata Limited

102 East Road
London N1 6AA , GB

Entity Type: 03

Trademark Details

Filing Date

December 11, 2000

Registration Date

September 26, 2006

Published for Opposition

October 18, 2005

Cancellation Date

May 3, 2013

Goods & Services

pharmaceutical preparations for medical diagnosis, namely, for the diagnosis of pregnancy; sanitary preparations, namely, tampons used for delivering pharmaceutical preparations to the female reproductive tract and tampons designed to reduce the chance of infection of the female reproductive tract; sanitary pads; sanitary napkins; dietetic products for medical use, namely, dietary supplements and food for medical restricted diets; diagnostic kits consisting primarily of medical diagnostic reagents and preparations for reproductive health uses, semen analysis, testing sperm fertilization capability, hormone level analysis for testing the presence and level of Luteneising Hormone (LH), Follicle Stimulating Hormone (FSH), Beta-Oestradiol, Prolactin, Progesterone, Human Chorionic Gonadotrophin (hCG) and Testosterone, to detect genital infections, to test for antibodies to various organisms, to detect markers of pre-term labor, pregnancy complications, miscarriage and implantation failure, to detect antiphospholipids, protein S deficiency, lupus anti-coagulant and factor V Leiden mutation, to detect markers of female fertility, to detect DAZL heterozygous mutation and associated biochemical markers such as testosterone for the analysis of DNA, RNA for the detection of disease or predisposition associated with reproduction, for the analysis of protein or other biochemical markers of disease or predisposition of disease, to detect biochemical markers which indicate disease or predisposition to disease; oral contraceptives; contraceptive foams

medical assistance, namely the provision of medical support staff to clinics and medical practices for the screening of patients, auditing and maintenance of records, and consultation regarding diagnoses and treatment options; nursing services, namely providing nursing staff to doctors, clinics, hospitals and medical practices

Healthcare services; medical clinics; midwife services; provision of information relating to health, wellbeing, nursing, medicine and healthcare via the Internet

diagnostic kits consisting primarily of dipsticks, litmus paper, test-tubes, pipettes, stylets for drawing blood samples, plastic containers, slides, syringes, needles, spatulas and non-invasive devices, and medical diagnostic reagents and preparations for obtaining and testing biological samples for reproductive health uses, semen analysis, testing sperm fertilization capability, hormone level analysis for testing the presence and level of Luteneising Hormone (LH), Follicle Stimulating Hormone (FSH), Beta-Qestradiol, Prolactin, Progesterone, Human ChorionicGonadotrophin (hCG) and Testosterone, to detect genital infections, to test for antibodies to various organisms, to detect markers of pre-term labor, pregnancy complications, miscarriage and implantation failure, to detect antiphospholipids, protein S deficiency, lupus anti-coagulant and factor V Leiden mutation, to detect markers of female fertility, to detect DAZL heterozygous mutation and associated biochemical markers such as testosterone for the analysis of DNA, RNA for the detection of disease or predisposition associated with reproduction, for the analysis of protein or other biochemical markers of disease or predisposition of disease, to detect biochemical markers which indicate disease or predisposition to disease; surgical and medical apparatus, namely, dipsticks, litmus paper, test-tubes, pipettes, stylets for drawing blood samples, plastic containers, slides, syringes, needles, spatulas and non-invasive devices for obtaining and testing biological samples; diaphragms for contraception; coils for contraception; protective sheaths for contraception

Scientific research and development of new products for others; technical consultation and research in the fields of health, wellbeing, nursing, medicine and healthcare

Filing History

CANCELLED SEC. 8 (6-YR)
May 3, 2013 C8..
REGISTERED-PRINCIPAL REGISTER
Sep 26, 2006 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jul 19, 2006 DP1B
NOTICE OF ALLOWANCE CANCELLED
Jul 7, 2006 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Jul 7, 2006 D1BR
NOTICE OF ALLOWANCE CORRECTION ENTERED
May 24, 2006 ICNA
FAX RECEIVED
May 2, 2006 FAXX
NOA MAILED - SOU REQUIRED FROM APPLICANT
Jan 10, 2006 NOAM
PUBLISHED FOR OPPOSITION
Oct 18, 2005 PUBO
NOTICE OF PUBLICATION
Sep 28, 2005 NPUB
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 19, 2005 TCCA
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 18, 2005 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 9, 2005 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 9, 2005 XAEC
ASSIGNED TO LIE
Jun 1, 2005 ALIE
EXAMINERS AMENDMENT E-MAILED
May 31, 2005 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 31, 2005 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
May 31, 2005 ZZZX
WITHDRAWN BEFORE PUBLICATION
May 16, 2005 CWBP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 16, 2005 PREV
ASSIGNED TO LIE
Feb 14, 2005 ALIE
ASSIGNED TO LIE
Jan 31, 2005 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 25, 2005 CNSA
EXAMINERS AMENDMENT E-MAILED
Jan 25, 2005 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 25, 2005 CNEA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 25, 2005 ZZZX
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 17, 2004 PREV
ASSIGNED TO LIE
Oct 4, 2004 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 29, 2004 CNSA
AMENDMENT FROM APPLICANT ENTERED
Sep 29, 2004 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 24, 2004 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 24, 2004 TROA
NON-FINAL ACTION MAILED
Mar 8, 2004 CNRT
CASE FILE IN TICRS
Nov 9, 2003 CFIT
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 24, 2003 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 24, 2003 TROA
NON-FINAL ACTION MAILED
Apr 25, 2003 CNRT
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 21, 2003 CRFA
PAPER RECEIVED
Mar 21, 2003 MAIL
INQUIRY AS TO SUSPENSION MAILED
Sep 23, 2002 CNSI
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 17, 2002 TCCA
LETTER OF SUSPENSION MAILED
Feb 5, 2002 CNSL
UNRESPONSIVE/DUPLICATE PAPER RECEIVED
Oct 15, 2001 UNPR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 11, 2001 CRFA
NON-FINAL ACTION MAILED
Apr 11, 2001 CNRT
ASSIGNED TO EXAMINER
Apr 4, 2001 DOCK